Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome
一项开放标签、对照的 II 期临床试验，旨在评估 INM004 在志贺毒素产大肠杆菌相关溶血性尿毒综合征患儿中的安全性、有效性和药代动力学。
期刊:Pediatric Nephrology
影响因子:2.6
doi:10.1007/s00467-024-06583-3
Fayad, Alicia; Principi, Iliana; Balestracci, Alejandro; Alconcher, Laura; Coccia, Paula; Adragna, Marta; Amoreo, Oscar; Bettendorff, María Carolina; Blumetti, María Valeria; Bonany, Pablo; Tonfi, María Laura Flores; Flynn, Luis; Ghezzi, Lidia; Montero, Jorge; Ramírez, Flavia; Seminara, Claudia; Suarez, Ángela; Spizzirri, Ana Paula; Rivas, Marta; Pichel, Mariana; Zylberman, Vanesa; Spatz, Linus; Massa, Carolina; Valerio, Marina; Sanguineti, Santiago; Colonna, Mariana; Roubicek, Ian; Goldbaum, Fernando
